Cinctive Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.98M Hold
275,000
0.26% 134
2025
Q4
$3.92M Buy
+275,000
New +$2.7M 0.21% 137
2020
Q4
Sell
-219,524
Closed -$3.1M 356
2020
Q3
$3.1M Buy
219,524
+51,314
+31% +$748K 0.27% 150
2020
Q2
$2.54M Sell
168,210
-108,347
-39% -$1.32M 0.29% 153
2020
Q1
$2.56M Sell
276,557
-202,343
-42% -$1.92M 0.57% 67
2019
Q4
$4.66M Buy
+478,900
New +$4.38M 0.49% 96

Other funds holding FOLD

Cinctive Capital Management's FOLD Position: Q1 2026 in Review

Cinctive Capital Management held its Amicus Therapeutics (FOLD) position steady in Q1 2026 at 275,000 shares worth $3.98M. The position accounts for 0.26% of the portfolio, ranked #134.

Cinctive Capital Management first reported a position in FOLD in Q4 2019 and has held it in 6 quarters since. The position peaked at $4.66M in Q4 2019. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Cinctive Capital Management held 275,000 shares of Amicus Therapeutics worth $3.98M as of Q1 2026.
  • Cinctive Capital Management left its Amicus Therapeutics share count unchanged in Q1 2026.
  • Amicus Therapeutics made up 0.26% of Cinctive Capital Management's portfolio in Q1 2026, its #134 holding.
  • Cinctive Capital Management first reported a position in Amicus Therapeutics in Q4 2019 and has held it in 6 quarters since.
  • Cinctive Capital Management's Amicus Therapeutics position peaked at $4.66M in Q4 2019.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Cinctive Capital Management's 13F filing for Q1 2026, filed 15 May 2026.